Skip to main content
SpringerLink
Log in

Diagnosis Threat Related to Disclosure of Alzheimer Disease Biomarkers and a Discussion of the Ethics in Clinical and Research Settings

  • Chapter
  • First Online:
Living with Dementia

Part of the book series: Advances in Neuroethics ((AIN))

  • 538 Accesses

Abstract

Diagnosis threat occurs when individuals have a negative expectation of behaviors or symptoms associated with a proposed diagnosis. For example, a member of a group may change their behavior or cognitive functioning because they are aware that such changes are typically expected of individuals in that group. In dementia, people may experience diagnosis threat because they have a reasonable expectation of how behavior or cognitive functioning changes in these conditions. Studies on diagnosis threat have demonstrated that by simply knowing of an increased risk of dementia, people will display declines in cognitive function and will self-report more memory concerns. However, studies demonstrate that not all individuals with a risk of dementia will develop the clinical manifestation of the disease. With increased medical advances in genetics and neuroimaging, people have increasing access to knowledge about their genetic risks and vulnerabilities, and doctors sometimes reveal these vulnerabilities to asymptomatic patients. This chapter reviews the important aspects of diagnosis threat correlated with revealing the risk of dementia in an asymptomatic population and how disclosures in this population might cause diagnosis threat and impact psychological well-being. Additional discussion includes clinical and research practice standards for the appropriate and ethical use of genetic and neuroimaging data associated with dementia risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.

    Article  Google Scholar 

  2. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–49.

    Article  Google Scholar 

  3. Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711–7. https://doi.org/10.2967/jnumed.116.185017.

    Article  PubMed  Google Scholar 

  4. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16.

    Article  CAS  Google Scholar 

  5. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–67.

    Article  CAS  Google Scholar 

  6. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–31.

    Article  CAS  Google Scholar 

  7. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578–86.

    Article  CAS  Google Scholar 

  8. Mormino E, Brandel M, Madison C. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. NeuroImage. 2012;59(2):1152–60.

    Article  Google Scholar 

  9. Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex. 2011;21(10):2399–407.

    Article  Google Scholar 

  10. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130(11):2837–44.

    Article  Google Scholar 

  11. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1, 2):117–28.

    Article  CAS  Google Scholar 

  12. Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS. Public attitudes about genetic testing for Alzheimer’s disease. Health Aff. 2001;20(5):252–64.

    Article  CAS  Google Scholar 

  13. Smedinga M, Tromp K, Schermer MHN, Richard E. Ethical arguments concerning the use of Alzheimer’s disease biomarkers in individuals with no or mild cognitive impairment: a systematic review and framework for discussion. J Alzheimers Dis. 2018;66(4):1309–22.

    Article  Google Scholar 

  14. Gooblar J, Roe CM, Selsor NJ, Gabel MJ, Morris JC. Attitudes of research participants and the general public regarding disclosure of Alzheimer disease research results. JAMA Neurol. 2015;72(12):1484–90. https://doi.org/10.1001/jamaneurol.2015.2875.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vanderschaeghe G, Schaeverbeke J, Vandenberghe R, Dierickx K. Amnestic MCI patients’ perspectives toward disclosure of amyloid PET results in a research context. Neuroethics. 2017;10(2):281–97. https://doi.org/10.1007/s12152-017-9313-z.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Vanderschaeghe G, Vandenberghe R, Dierickx K. Stakeholders’ views on early diagnosis for Alzheimer’s disease, clinical trial participation and amyloid PET disclosure: a focus group study. J Bioethical Inquiry. 2019;16(1):45–59. https://doi.org/10.1007/s11673-019-09901-9.

    Article  Google Scholar 

  17. Suhr JA, Gunstad J. “Diagnosis threat”: the effect of negative expectations on cognitive performance. J Clin Exp Neuropsychol. 2002;24(4):448–57.

    Article  Google Scholar 

  18. Smith JL. Understanding the process of stereotype threat: a review of mediational variables and new performance goal directions. Educ Psychol Rev. 2004;16(3):177–206.

    Article  Google Scholar 

  19. Suhr JA, Gunstad J. Further exploration of the effect of “diagnosis threat” on cognitive performance in individuals with mild head injury. J Int Neuropsychol Soc. 2005;11(1):23–9.

    Article  Google Scholar 

  20. Trontel HG, Hall S, Ashendorf L, O’Connor MK. Impact of diagnosis threat on academic self-efficacy in mild traumatic brain injury. J Clin Exp Neuropsychol. 2013;35(9):960–70.

    Article  Google Scholar 

  21. Rue AL, Small G, McPherson S, Komo S, Matsuyama SS, Jarvik LF. Subjective memory loss in age-associated memory impairment: family history and neuropsychological correlates. Aging Neuropsychol Cognit. 1996;3(2):132–40.

    Article  Google Scholar 

  22. McPherson S, La Rue A, Fitz A, Matsuyama S, Jarvik LF. Self-reports of memory problems in relatives of patients with probable Alzheimer’s disease. Int Psychogeriatr. 1995;7:367–76.

    Article  CAS  Google Scholar 

  23. Hess T, Hinson JT. Age-related variation in the influences of aging stereotypes on memory in adulthood. Psychol Aging. 2006;21(3):621–5.

    Article  Google Scholar 

  24. Hess T, Hinson J, Statham J. Explicit and implicit stereotype activation effects on memory: do age and awareness moderate the impact of priming? Psychol Aging. 2004;19(3):495–505.

    Article  Google Scholar 

  25. Hess TM, Auman C, Colcombe SJ, Rahhal TA. The impact of stereotype threat on age differences in memory performance. J Gerontol Ser B Psychol Sci Soc Sci. 2003;58(1):P3–P11.

    Google Scholar 

  26. Levy B. Improving memory in old age through implicit self-stereotyping. J Pers Soc Psychol. 1996;71(6):1092–107.

    Article  CAS  Google Scholar 

  27. Desrichard O, Köpetz C. A threat in the elder: the impact of task-instructions, self-efficacy and performance expectations on memory performance in the elderly. Eur J Soc Psychol. 2005;35(4):537–52.

    Article  Google Scholar 

  28. Chasteen AL, Bhattacharyya S, Horhota M, Tam R, Hasher L. How feelings of stereotype threat influence older adults’ memory performance. Exp Aging Res. 2005;31(3):235–60.

    Article  Google Scholar 

  29. Mazerolle M, Regner I, Barber SJ, Paccalin M, Miazola AC, Huguet P, Rigalleau F. Negative aging stereotypes impair performance on brief cognitive tests used to screen for predementia. J Gerontol Ser B Psychol Sci Soc Sci. 2017;72(6):932–6.

    Google Scholar 

  30. Fresson M, Dardenne B, Geurten M, Meulemans T. The effect of stereotype threat on older people’s clinical cognitive outcomes: investigating the moderating role of dementia worry. Clin Neuropsychol. 2017;31(8):1306–28. https://doi.org/10.1080/13854046.2017.1307456.

  31. Lineweaver T, Bondi M, Galasko D, Salmon D. Knowledge of APOE genotype affects subjective and objective memory performance in healthy older adults. Am J Psychiatr. 2013;171(2):201–8.

    Article  Google Scholar 

  32. Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T, American College of Medical Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of genetic counselors. Genet Med. 2011;13(6):597–605. https://doi.org/10.1097/GIM.0b013e31821d69b8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, et al. Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8(1) https://doi.org/10.1186/s13195-016-0212-z.

  34. Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024–30.

    Article  Google Scholar 

  35. Lim YY, Maruff P, Getter C, Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454–8. https://doi.org/10.1016/j.jalz.2015.09.005.

    Article  PubMed  Google Scholar 

  36. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med. 2009;361(3):245–54. https://doi.org/10.1056/NEJMoa0809578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord. 2008;22(1):94.

    Article  Google Scholar 

  38. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC, REVEAL (Risk Evaluation and Education for Alzheimer’s Disease) Study Group. Genetic risk assessment for adult children of people with Alzheimer’s disease: the risk evaluation and education for Alzheimer’s disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005;18(4):250–5.

    Article  Google Scholar 

  39. Grill JD, Cox CG, Harkins K, Karlawish J. Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial. Alzheimers Res Ther. 2018;10(1):125. https://doi.org/10.1186/s13195-018-0452-1.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Johnson K, Minoshima S, Bohnen N, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment and education. Alzheimers Dement. 2013a;9(4):e106–9.

    Article  Google Scholar 

  41. Johnson K, Minoshima S, Bohnen N, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med. 2013b;54(3):14.

    Article  Google Scholar 

  42. Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement. 2013;9(6):741–4.

    Article  Google Scholar 

  43. Klein EP, Kaye J. Dementia specialists and early adoption of amyloid imaging. J Alzheimers Dis. 2013;33(2):445–50.

    Article  Google Scholar 

  44. Shulman MB, Harkins K, Green RC, Karlawish J. Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81(13):1114–21.

    Article  CAS  Google Scholar 

  45. Vanderschaeghe G, Schaeverbeke J, Bruffaerts R, Vandenberghe R, Dierickx K. From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting. Alzheimers Dement. 2018;4:243–51. https://doi.org/10.1016/j.trci.2018.04.002.

    Article  Google Scholar 

  46. Department of Health, Education, and Welfare, & National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report. Ethical principles and guidelines for the protection of human subjects of research. J Am Coll Dent. 2014;81(3):4–13.

    Google Scholar 

  47. Riddick FA Jr. The code of medical ethics of the American medical association. Ochsner J. 2003;5(2):6–10.

    PubMed  PubMed Central  Google Scholar 

  48. American Psychological Association. Ethical principles of psychologists and code of conduct (2002, amended effective June 1, 2010, and January 1, 2017). 2017. http://www.apa.org/ethics/code/index.html.

  49. de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, et al. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers Res Ther. 2018;10(1):72. https://doi.org/10.1186/s13195-018-0398-3.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Grill JD, Karlawish J. Study partners should be required in preclinical Alzheimer’s disease trials. Alzheimers Res Ther. 2017;9(1):93. https://doi.org/10.1186/s13195-017-0327-x.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University Medical Center, Durham, NC, USA

    Thomas J. Farrer & Sarah E. Cook

Authors
  1. Thomas J. Farrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah E. Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. Farrer .

Editor information

Editors and Affiliations

  1. Department of Philosophy and Religious Studies, and Science Technology and Society (STS) Program, North Carolina State University, Raleigh, NC, USA

    Veljko Dubljević

  2. Department of Philosophy, University of North Carolina, Greensboro, NC, USA

    Frances Bottenberg

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Farrer, T.J., Cook, S.E. (2021). Diagnosis Threat Related to Disclosure of Alzheimer Disease Biomarkers and a Discussion of the Ethics in Clinical and Research Settings. In: Dubljević, V., Bottenberg, F. (eds) Living with Dementia. Advances in Neuroethics. Springer, Cham. https://doi.org/10.1007/978-3-030-62073-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62073-8_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62072-1

  • Online ISBN: 978-3-030-62073-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation